metformin has been researched along with Kidney Neoplasms in 36 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Kidney Neoplasms: Tumors or cancers of the KIDNEY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Both bortezomib and metformin have been proposed as potential therapeutics in TSC." | 5.38 | Therapeutic trial of metformin and bortezomib in a mouse model of tuberous sclerosis complex (TSC). ( Auricchio, N; Kwiatkowski, DJ; Malinowska, I; Manning, BD; Shaw, R, 2012) |
| "To evaluate the effect of metformin combined with intensive-exercise diet therapy on glucose and lipid metabolism and islet function in diabetes patients with localized renal cell carcinoma after laparoscopic resection." | 3.11 | A Randomized Study on the Effect of Metformin Combined with Intensive-Exercise Diet Therapy on Glucose and Lipid Metabolism and Islet Function in Patients with Renal Cell Carcinoma and Diabetes. ( An, RH; Jin, YS; Li, JW; Liu, Y; Meng, LL, 2022) |
| "Metformin has been associated with improved survival outcomes in various malignancies." | 2.61 | Metformin Use and Kidney Cancer Survival Outcomes: A Systematic Review and Meta-Analysis. ( Austin, PC; Finelli, A; Hamilton, RJ; Juurlink, DN; Kulkarni, GS; Nayan, M; Punjani, N; Uleryk, E, 2019) |
| "Metformin is an antidiabetic drug; recent reports have indicated its anti-cancer effects in various cancers, and it is known to have synergistic effects with other drugs." | 1.72 | Synergic Effect of Metformin and Everolimus on Mitochondrial Dynamics of Renal Cell Carcinoma. ( Han, WK; Hong, SH; Hwang, HJ; Lee, KS; Park, SY; Yoon, YE, 2022) |
| "Clear cell renal cell carcinoma (ccRCC) is the most common and lethal form of urological cancer diagnosed globally." | 1.51 | Metformin Induces Different Responses in Clear Cell Renal Cell Carcinoma Caki Cell Lines. ( Agouni, A; Frantz, R; Munusamy, S; Pasha, M; Sivaraman, SK, 2019) |
| "Metformin (Met) is a widely available diabetic drug and shows suppressed effects on renal cell carcinoma (RCC) metabolism and proliferation." | 1.48 | Valproic acid sensitizes metformin-resistant human renal cell carcinoma cells by upregulating H3 acetylation and EMT reversal. ( Chen, Y; Huang, Z; Lan, X; Li, L; Lu, G; Mao, S; Wei, M; Xia, Q; Zhao, M; Zhao, Y, 2018) |
| "Metformin use has been associated previously with a decreased risk of cancer, but its association with renal cell carcinoma has not yet been investigated in observational studies." | 1.46 | Metformin and the risk of renal cell carcinoma: a case-control analysis. ( Becker, C; Bodmer, M; Jick, SS; Meier, CR, 2017) |
| "Metformin use was not significantly associated with disease-free (hazard ratio [HR], 0." | 1.46 | Metformin Use and Kidney Cancer Outcomes in Patients With Diabetes: A Propensity Score Analysis. ( Austin, PC; Finelli, A; Hamilton, RJ; Jewett, MA; Juurlink, DN; Kulkarni, GS; Nayan, M, 2017) |
| "Metformin (MF) acts as a tumour-suppressor in renal cell carcinoma (RCC) by inhibiting the AKT/mTOR pathway via AMPK activation." | 1.43 | Metformin-Derived Growth Inhibition in Renal Cell Carcinoma Depends on miR-21-Mediated PTEN Expression. ( Kalogirou, C; Kneitz, B; Krebs, M; Kurz, F; Riedmiller, H; Schäfer, D; Schneider, A; Vergho, D, 2016) |
| "With respect to kidney cancer scarce data are available." | 1.43 | Use of metformin and risk of kidney cancer in patients with type 2 diabetes. ( Tseng, CH, 2016) |
| " Limitations include retrospective design and lack of data on metformin dosage and duration of use." | 1.43 | Metformin Use in Relation With Survival Outcomes of Patients With Renal Cell Carcinoma. ( Cheng, JJ; Kanesvaran, R; Li, H; Ng, LG; Ng, QS; Tan, HS; Tan, MH; Tan, PH; Toh, CK, 2016) |
| "Metformin inhibits renal cell carcinoma (RCC) cell proliferation both in vitro and in vivo; however, clinical data regarding the effect of metformin in patients with RCC are lacking." | 1.42 | The association between metformin use and oncologic outcomes among surgically treated diabetic patients with localized renal cell carcinoma. ( Boorjian, SA; Cheville, JC; Leibovich, BC; Lohse, CM; Psutka, SP; Stewart, SB; Thompson, RH; Tollefson, MK, 2015) |
| "Medical records of 1087 patients with type 2 diabetes were retrospectively analyzed and a group of 74 (6." | 1.42 | [Obesity as a factor in the development of cancer in type 2 diabetes]. ( Chodorowska, M; Jakubowska, I; Łukasiewicz, D, 2015) |
| "Oncocytomas are predominantly benign neoplasms possessing pathogenic mitochondrial mutations and accumulation of respiration-defective mitochondria, characteristics of unknown significance." | 1.42 | The Genomic Landscape of Renal Oncocytoma Identifies a Metabolic Barrier to Tumorigenesis. ( Aviv, H; Chan, CS; Ganesan, S; Hakimi, AA; Hsieh, JJ; Joshi, S; Tolkunov, D; White, E; Yao, M, 2015) |
| "Metformin was able to induce G0/G1 cell cycle arrest and inhibit RCC growth in vitro and in vivo." | 1.39 | Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft. ( Bai, X; Hu, W; Jia, C; Li, M; Liu, J; Song, B; Zhang, L, 2013) |
| "Metformin treatment appeared to attenuate mTORC1 signalling in Tsc1(+/-) kidney tissues but not in renal tumours." | 1.39 | Renal tumours in a Tsc1+/- mouse model show epigenetic suppression of organic cation transporters Slc22a1, Slc22a2 and Slc22a3, and do not respond to metformin. ( Gallacher, J; Kalogerou, M; Sampson, JR; Shen, MH; Yang, J, 2013) |
| "Both bortezomib and metformin have been proposed as potential therapeutics in TSC." | 1.38 | Therapeutic trial of metformin and bortezomib in a mouse model of tuberous sclerosis complex (TSC). ( Auricchio, N; Kwiatkowski, DJ; Malinowska, I; Manning, BD; Shaw, R, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.78) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 28 (77.78) | 24.3611 |
| 2020's | 7 (19.44) | 2.80 |
| Authors | Studies |
|---|---|
| Yao, X | 1 |
| Liu, H | 1 |
| Xu, H | 1 |
| Liu, Y | 2 |
| Li, J | 1 |
| Song, M | 1 |
| Qi, G | 1 |
| Meng, L | 1 |
| Meng, LL | 1 |
| Li, JW | 1 |
| Jin, YS | 1 |
| An, RH | 1 |
| Hong, SH | 1 |
| Lee, KS | 1 |
| Hwang, HJ | 1 |
| Park, SY | 1 |
| Han, WK | 1 |
| Yoon, YE | 1 |
| Santoni, M | 1 |
| Molina-Cerrillo, J | 1 |
| Myint, ZW | 1 |
| Massari, F | 1 |
| Buchler, T | 1 |
| Buti, S | 1 |
| Matrana, MR | 1 |
| De Giorgi, U | 1 |
| Rizzo, M | 1 |
| Zabalza, IO | 1 |
| Galli, L | 1 |
| Zucali, PA | 1 |
| Aurilio, G | 1 |
| Incorvaia, L | 1 |
| Bassanelli, M | 1 |
| Mammone, G | 1 |
| Salfi, A | 1 |
| Isella, L | 1 |
| Mollica, V | 1 |
| Grande, E | 1 |
| Porta, C | 1 |
| Battelli, N | 1 |
| Li, H | 3 |
| Zhang, L | 3 |
| Yang, F | 2 |
| Zhao, R | 1 |
| Li, X | 1 |
| Shi, H | 1 |
| Sun, Y | 1 |
| He, M | 1 |
| Yang, X | 1 |
| Hamada, M | 1 |
| Fukunaga, T | 1 |
| Zhang, X | 3 |
| Chang, C | 1 |
| Takahashi, M | 1 |
| Inoue, T | 1 |
| Huang, M | 1 |
| Numakura, K | 1 |
| Tsuruta, H | 1 |
| Saito, M | 1 |
| Maeno, A | 1 |
| Nakamura, E | 1 |
| Narita, S | 1 |
| Tsuchiya, N | 1 |
| Habuchi, T | 1 |
| Wei, M | 1 |
| Mao, S | 1 |
| Lu, G | 1 |
| Li, L | 1 |
| Lan, X | 1 |
| Huang, Z | 1 |
| Chen, Y | 1 |
| Zhao, M | 1 |
| Zhao, Y | 1 |
| Xia, Q | 2 |
| Nayan, M | 2 |
| Punjani, N | 1 |
| Juurlink, DN | 2 |
| Finelli, A | 2 |
| Austin, PC | 2 |
| Kulkarni, GS | 2 |
| Uleryk, E | 1 |
| Hamilton, RJ | 2 |
| Liu, M | 2 |
| Zhang, Z | 1 |
| Wang, H | 1 |
| Chen, X | 1 |
| Jin, C | 1 |
| Pasha, M | 1 |
| Sivaraman, SK | 1 |
| Frantz, R | 1 |
| Agouni, A | 1 |
| Munusamy, S | 1 |
| Rieken, M | 1 |
| Xylinas, E | 1 |
| Kluth, L | 1 |
| Trinh, QD | 1 |
| Lee, RK | 1 |
| Fajkovic, H | 1 |
| Novara, G | 1 |
| Margulis, V | 1 |
| Lotan, Y | 1 |
| Martinez-Salamanca, JI | 1 |
| Matsumoto, K | 1 |
| Seitz, C | 1 |
| Remzi, M | 1 |
| Karakiewicz, PI | 1 |
| Scherr, DS | 1 |
| Briganti, A | 1 |
| Kautzky-Willer, A | 1 |
| Bachmann, A | 1 |
| Shariat, SF | 1 |
| Psutka, SP | 1 |
| Boorjian, SA | 1 |
| Lohse, CM | 1 |
| Stewart, SB | 1 |
| Tollefson, MK | 1 |
| Cheville, JC | 1 |
| Leibovich, BC | 1 |
| Thompson, RH | 1 |
| Łukasiewicz, D | 1 |
| Chodorowska, M | 1 |
| Jakubowska, I | 1 |
| Huang, T | 1 |
| Geng, J | 1 |
| Zheng, J | 1 |
| Kalogirou, C | 1 |
| Schäfer, D | 1 |
| Krebs, M | 1 |
| Kurz, F | 1 |
| Schneider, A | 2 |
| Riedmiller, H | 1 |
| Kneitz, B | 1 |
| Vergho, D | 1 |
| Tseng, CH | 2 |
| Joshi, S | 2 |
| Tolkunov, D | 1 |
| Aviv, H | 1 |
| Hakimi, AA | 1 |
| Yao, M | 1 |
| Hsieh, JJ | 1 |
| Ganesan, S | 1 |
| Chan, CS | 1 |
| White, E | 1 |
| Cheng, JJ | 1 |
| Tan, HS | 1 |
| Tan, PH | 1 |
| Ng, LG | 1 |
| Ng, QS | 1 |
| Toh, CK | 1 |
| Kanesvaran, R | 1 |
| Tan, MH | 1 |
| Becker, C | 1 |
| Jick, SS | 1 |
| Meier, CR | 1 |
| Bodmer, M | 1 |
| de Jong, RG | 1 |
| Nielen, JT | 1 |
| Masclee, AA | 1 |
| Janssen-Heijnen, ML | 1 |
| de Vries, F | 1 |
| Sayyid, RK | 1 |
| Fleshner, NE | 1 |
| Keizman, D | 1 |
| Ish-Shalom, M | 1 |
| Sella, A | 1 |
| Gottfried, M | 1 |
| Maimon, N | 1 |
| Peer, A | 1 |
| Hammers, H | 1 |
| Eisenberger, MA | 1 |
| Sinibaldi, V | 1 |
| Neiman, V | 1 |
| Rosenbaum, E | 1 |
| Sarid, D | 1 |
| Mermershtain, W | 1 |
| Rouvinov, K | 1 |
| Berger, R | 1 |
| Carducci, MA | 1 |
| Jewett, MA | 1 |
| Hamieh, L | 1 |
| McKay, RR | 1 |
| Lin, X | 1 |
| Moreira, RB | 1 |
| Simantov, R | 1 |
| Choueiri, TK | 1 |
| Xie, W | 1 |
| Wang, L | 1 |
| Sheng, H | 1 |
| Qiu, J | 1 |
| Zhang, D | 1 |
| Tang, D | 1 |
| Zhang, K | 1 |
| Li, Y | 1 |
| Hu, L | 1 |
| Yuan, Y | 1 |
| Mi, Y | 1 |
| Woodard, J | 1 |
| Viollet, B | 1 |
| Hay, N | 1 |
| Platanias, LC | 1 |
| Gartenhaus, RB | 1 |
| Liu, J | 2 |
| Li, M | 2 |
| Song, B | 1 |
| Jia, C | 1 |
| Bai, X | 1 |
| Hu, W | 1 |
| Hu, WL | 1 |
| Jia, CH | 1 |
| Li, HY | 1 |
| Wen, ZH | 1 |
| Zou, ZP | 1 |
| Bai, XC | 1 |
| Luo, SQ | 1 |
| Auricchio, N | 1 |
| Malinowska, I | 1 |
| Shaw, R | 1 |
| Manning, BD | 1 |
| Kwiatkowski, DJ | 1 |
| Yang, J | 1 |
| Kalogerou, M | 1 |
| Gallacher, J | 1 |
| Sampson, JR | 1 |
| Shen, MH | 1 |
| Gowardman, JR | 1 |
| Havill, J | 1 |
5 reviews available for metformin and Kidney Neoplasms
| Article | Year |
|---|---|
The Impact of Metformin Use with Survival Outcomes in Urologic Cancers: A Systematic Review and Meta-Analysis.
Topics: China; Humans; Hypoglycemic Agents; Kidney Neoplasms; Male; Metformin; Prognosis; Prostatic Neoplasm | 2021 |
Impact of concomitant medications on the efficacy of immune checkpoint inhibitors: an umbrella review.
Topics: Analgesics, Opioid; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Esophag | 2023 |
Metformin Use and Kidney Cancer Survival Outcomes: A Systematic Review and Meta-Analysis.
Topics: Humans; Hypoglycemic Agents; Kidney Neoplasms; Metformin; Prognosis; Survival Rate | 2019 |
Potential role for metformin in urologic oncology.
Topics: Anticarcinogenic Agents; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Mal | 2016 |
The impact of metformin use on survival in kidney cancer patients with diabetes: a meta-analysis.
Topics: Carcinoma, Renal Cell; Diabetes Mellitus; Disease-Free Survival; Humans; Hypoglycemic Agents; Kidney | 2017 |
1 trial available for metformin and Kidney Neoplasms
| Article | Year |
|---|---|
A Randomized Study on the Effect of Metformin Combined with Intensive-Exercise Diet Therapy on Glucose and Lipid Metabolism and Islet Function in Patients with Renal Cell Carcinoma and Diabetes.
Topics: Blood Glucose; Carcinoma, Renal Cell; Cholesterol; Diabetes Mellitus, Type 2; Glucose; Humans; Hypog | 2022 |
30 other studies available for metformin and Kidney Neoplasms
| Article | Year |
|---|---|
High-Concentration Metformin Reduces Oxidative Stress Injury and Inhibits the Growth and Migration of Clear Cell Renal Cell Carcinoma.
Topics: Carcinoma, Renal Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclin D; Humans; Kidney | 2022 |
Synergic Effect of Metformin and Everolimus on Mitochondrial Dynamics of Renal Cell Carcinoma.
Topics: Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Everolimus; Humans; Kidney Neoplasms; M | 2022 |
Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination Therapies.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibito | 2022 |
Targeting the TR4 nuclear receptor-mediated lncTASR/AXL signaling with tretinoin increases the sunitinib sensitivity to better suppress the RCC progression.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Axl Receptor Tyrosine Kinase; Carcinoma, Re | 2020 |
Inverse relationship between insulin receptor expression and progression in renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antigens, CD; Carcinoma, Renal Cell; Diet, Carbohydrate Loa | 2017 |
Valproic acid sensitizes metformin-resistant human renal cell carcinoma cells by upregulating H3 acetylation and EMT reversal.
Topics: Acetylation; Apoptosis; Carcinoma, Renal Cell; Cell Cycle; Cell Line, Tumor; Cell Movement; Drug Res | 2018 |
Activation of AMPK by metformin promotes renal cancer cell proliferation under glucose deprivation through its interaction with PKM2.
Topics: AMP-Activated Protein Kinases; Animals; Carrier Proteins; Cell Line, Tumor; Cell Proliferation; Huma | 2019 |
Metformin Induces Different Responses in Clear Cell Renal Cell Carcinoma Caki Cell Lines.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Cell Movement; Cell Proliferation; Cell Sur | 2019 |
Diabetes mellitus without metformin intake is associated with worse oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma.
Topics: Aged; Carcinoma, Transitional Cell; Diabetes Mellitus; Female; Follow-Up Studies; Humans; Hypoglycem | 2014 |
The association between metformin use and oncologic outcomes among surgically treated diabetic patients with localized renal cell carcinoma.
Topics: Aged; Carcinoma, Renal Cell; Cohort Studies; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; | 2015 |
[Obesity as a factor in the development of cancer in type 2 diabetes].
Topics: Aged; Breast Neoplasms; Colorectal Neoplasms; Comorbidity; Diabetes Mellitus, Type 2; Female; Humans | 2015 |
Combination of metformin and valproic acid synergistically induces cell cycle arrest and apoptosis in clear cell renal cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Renal Cell; Cell Cycle Checkpo | 2015 |
Metformin-Derived Growth Inhibition in Renal Cell Carcinoma Depends on miR-21-Mediated PTEN Expression.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Female; | 2016 |
Use of metformin and risk of kidney cancer in patients with type 2 diabetes.
Topics: Adult; Aged; Databases, Factual; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Inc | 2016 |
The Genomic Landscape of Renal Oncocytoma Identifies a Metabolic Barrier to Tumorigenesis.
Topics: Adenoma, Oxyphilic; AMP-Activated Protein Kinases; Autophagy; Carcinoma, Renal Cell; Cathepsins; Cel | 2015 |
Metformin Use in Relation With Survival Outcomes of Patients With Renal Cell Carcinoma.
Topics: Aged; Carcinoma, Renal Cell; Diabetes Mellitus; Female; Humans; Kidney Neoplasms; Male; Metformin; M | 2016 |
Metformin and the risk of renal cell carcinoma: a case-control analysis.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Case-Control Studies; Diabetes Mellitus; Fema | 2017 |
Comments on "Use of metformin and risk of kidney cancer in patients with type 2 diabetes", Chin-Hsiao Tseng, Eur J Cancer, 2016, No. 52, pp. 19-25.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Kidney Neoplasms; Metformin; Risk | 2016 |
Response to Letter to the Editor on comments on Use of metformin and risk of kidney cancer in patients with type 2 diabetes Chin-Hsiao Tseng, Eur J Cancer, 2016, No. 52, pp. 19-25.
Topics: Diabetes Mellitus, Type 2; Humans; Kidney Neoplasms; Metformin; Risk | 2016 |
Metformin Use and Outcome of Sunitinib Treatment in Patients With Diabetes and Metastatic Renal Cell Carcinoma.
Topics: Aged; Aged, 80 and over; Carcinoma, Renal Cell; Comorbidity; Diabetes Mellitus; Disease-Free Surviva | 2016 |
Metformin Use and Kidney Cancer Outcomes in Patients With Diabetes: A Propensity Score Analysis.
Topics: Aged; Aged, 80 and over; Carcinoma, Renal Cell; Diabetes Mellitus; Disease-Free Survival; Female; Hu | 2017 |
Effect of Metformin Use on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, P | 2017 |
Metformin Induces Growth Inhibition and Cell Cycle Arrest by Upregulating MicroRNA34a in Renal Cancer Cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Cell Cycle Checkpoints; Cell Line, Tumor; C | 2017 |
AMPK as a therapeutic target in renal cell carcinoma.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Carcinoma, Renal Cell; Cell Growth Proces | 2010 |
AMPK signaling: a targetable tumor suppressor pathway?
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Carcinoma, Renal Cell; Humans; Kidney Neo | 2010 |
Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Renal Cell; Cell Cycle; Cell Line, Tum | 2013 |
[Effect of metformin on apoptosis of renal cell carcinoma cells in vitro and its mechanisms].
Topics: Apoptosis; Carcinoma, Renal Cell; Caspase 9; Cell Line, Tumor; Cell Proliferation; Humans; Kidney Ne | 2011 |
Therapeutic trial of metformin and bortezomib in a mouse model of tuberous sclerosis complex (TSC).
Topics: Animals; Body Weight; Boronic Acids; Bortezomib; Disease Models, Animal; Humans; Immunoblotting; Imm | 2012 |
Renal tumours in a Tsc1+/- mouse model show epigenetic suppression of organic cation transporters Slc22a1, Slc22a2 and Slc22a3, and do not respond to metformin.
Topics: Animals; Azacitidine; Blotting, Western; Catecholamine Plasma Membrane Transport Proteins; Decitabin | 2013 |
Fatal metformin induced lactic acidosis: case report.
Topics: Acidosis, Lactic; Fatal Outcome; Female; Humans; Kidney Neoplasms; Metformin; Middle Aged; Postopera | 1995 |